Friday, August 19, 2022

Great Bay Bio Officially Launches AI Enabled Cell Culture Media Development Platform, AlfaMedX®

Last updated Wednesday, March 31, 2021 13:21 ET , Source: Great Bay Bio

Great Bay Bio Officially Launches AI Enabled Cell Culture Media Development Platform, AlfaMedX®

Hong Kong, HK, 03/31/2021 / SubmitMyPR /

Great Bay Bio Holdings Limited (hereinafter referred to as “GBB”) is pleased to announce that the company’s self-developed AI-enabled cell culture media development platform, AlfaMedX®, is officially launched. AlfaMedX® is created through the convergence between AI, big data, and biotechnology, enabling the development of optimized cell culture media within a short timeframe of 2 months, thus partially solving the pain points of “high cost, long development cycle and high risk” in the biopharmaceutical industry.

Cell culture media is an essential “nutrient” in biotechnology manufacturing processes across different industries, including biologic therapeutics, cell therapies, gene therapies and even new meat substitutes. However, rapid development of an optimized, high-quality cell culture media has always been a challenge, and therefore companies choose to use expensive commercially available cell culture media, which significantly dictate downstream development and manufacturing cost, and is sensitive to supply chain risk. Hence, the AlfaMedX®use case is extremely attractive, capable of reducing development time and cost up to 80%of customizable cell culture media and still delivering similar results as commercially available cell culture media, biotechnology enterprises will now have another lever to maintain their cost-effectiveness amongst cut-throat competition.

“We used thousands of formulations to train our algorithm and worked with several partners during the trial period to validate the platform, the result of which verifies AlfaMedX®’s advantageous functions.” said Dr. Michael Chen, CEO of Great Bay Bio, “We also successfully launched AI-enabled cell line development platform Klone4.0 back in October 2020. By utilizing both Klone 4.0TM and AlfaMedX® platforms in tandem, we successfully picked out high producing cell lines and, concurrently, customized media for those cell lines within 4 months, a feat that greatly outpaces what traditional methods can achieve.”

About Great Bay Bio

Headquartered in Hong Kong, GBB is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to biopharmaceutical development and other blue ocean bio-products, ultimately solving numerous pain points of the biopharmaceutical industry, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development in its 3100 m2 CMC facilities. With over USD$46M investment, the facilities bolster advanced equipment from world-renowned manufacturers. GBB has also successfully brought a number of biologic products to the NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created an intelligent centralized database, where deep learning is being performed to create the next generation of AI-enabled bioprocessing ecosystem. To learn more, please visit http://www.greatbay-bio.com.

Media Contact

Business cooperation: Eileen Ye

Organization: Great Bay Bio

Email: [email protected]

Location: Hong Kong

This content is published on behalf of the above source. Please contact them directly for any concern related to the above. 

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.